Skip to main content
Clinical Trials/NCT07516808
NCT07516808
Not yet recruiting
Not Applicable

PRISM-NLM: Prostatectomy Intraoperative Surgical Margin Assessment With Non-linear Microscopy

Beth Israel Deaconess Medical Center1 site in 1 country20 target enrollmentStarted: June 1, 2026Last updated:

Overview

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
20
Locations
1
Primary Endpoint
Enrollment Success Rate

Overview

Brief Summary

This study will evaluate the use of intraoperative nonlinear microscopy (NLM) for surgical margin assessment during nerve-sparing radical prostatectomy in participants with prostate cancer.

Detailed Description

This prospective, single-arm feasibility study is to evaluate the use of intraoperative nonlinear microscopy (NLM) for surgical margin assessment during nerve-sparing robot-assisted laparoscopic radical prostatectomy (RP) in participants with prostate cancer. A nonlinear microscope is a rapid imaging technology that can quickly image the surface of the prostate after it has been removed from the body to see if there is any cancer left behind.

The U.S. Food and Drug Administration (FDA) has not approved the NLM device for use in assessing radical prostatectomy surgical specimens but has been approved for other uses.

The research study procedures include screening for eligibility and standard of care radical prostatectomy surgery.

It is expected about 20 people will participate in this research study.

The National Institutes of Health is supporting this research study by providing study funds.

The Masssachusetts Institute of Technology (MIT) is supporting this research by providing the nonlinear microscope.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
Male
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age ≥ 18 years old.
  • Male or assigned male at birth (AMAB).
  • Initial diagnosis of localized PrCa.
  • Undergoing radical prostatectomy at BIDMC as part of their standard of care.

Exclusion Criteria

  • No short-form available in the participant's language.
  • Cognitively unable to provide consent, in the opinion of the investigator.
  • Patients with evidence of unequivocal radiologic bilateral extraprostatic extension (EPE) on most recent MRI results.
  • Patients with \>80 cc prostate volume (larger prostates would require potentially excessive evaluation time).

Arms & Interventions

Nonlinear Microscopy

Experimental

Enrolled participants will undergo standard-of-care robot-assisted radical prostatectomy surgery utilizing NLM (Nonlinear Microscopy)

Intervention: Nonlinear Microscope (NLM) (Device)

Outcomes

Primary Outcomes

Enrollment Success Rate

Time Frame: From screening through informed consent completion (up to Day 0 or baseline visit).

Enrollment success rate is defined as the proportion of eligible participants enrolled relative to the prespecified enrollment target.

Retention Success Rate

Time Frame: Up to 30 days post-surgery.

Retention success rate is defined as the probability of enrolled participants who completed the required study procedures and the follow-up period.

Technical and Workflow Feasibility Rate

Time Frame: On the day of robot-assisted radical prostatectomy (Day 0)

Feasibility rate is defined as the proportion of enrolled participants undergoing robot-assisted radical prostatectomy for whom intraoperative NLM-based specimen margin evaluation meets all predefined feasibility criteria, including timely actionable pathologic feedback, effective real-time communication, and the ability to perform secondary NVB resection when indicated.

Secondary Outcomes

  • Concordance of Surgical Margin Status Between Intraoperative Nonlinear Microscopy (NLM) and Postoperative Formalin-Fixed Paraffin-Embedded Hematoxylin and Eosin (FFPE H&E) Assessment(Up to 30 days post-surgery.)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Peter Chang

Principal Invesitgator

Beth Israel Deaconess Medical Center

Study Sites (1)

Loading locations...

Similar Trials